Intellia Therapeutics IPO
Intellia Therapeutics is a leading genome editing company developing CRISPR/Cas9-based therapeutics for genetic diseases. The company focuses on both in vivo and ex vivo approaches to treat conditions like transthyretin amyloidosis and primary hyperoxaluria. Investors are attracted to its clinical progress and potential for first-in-class treatments.
What We Know
Intellia Therapeutics completed its IPO in May 2016, raising approximately $108 million on NASDAQ under the ticker NTLA. The company priced its shares at $16 each, above the initial expected range, reflecting strong investor demand for CRISPR therapeutics exposure. Since going public, Intellia has made significant clinical progress, particularly with its in vivo CRISPR programs. The stock has seen substantial volatility, with notable spikes following positive clinical data releases, particularly for its transthyretin amyloidosis program which demonstrated proof-of-concept for in vivo gene editing.
Frequently Asked Questions
Has Intellia Therapeutics had an IPO?
Yes, Intellia Therapeutics completed its IPO in May 2016. The company has been publicly traded on NASDAQ under the ticker NTLA since then.
When is the Intellia Therapeutics IPO date?
Intellia Therapeutics already completed its IPO on May 5, 2016. The company is currently trading as a public biotechnology stock on NASDAQ.
How can I buy Intellia Therapeutics stock?
You can buy Intellia Therapeutics stock through any brokerage account since it trades publicly on NASDAQ under the ticker NTLA. The stock is available for purchase during regular market hours like other publicly traded securities.
Don't Miss the Next Big IPO
Get notified when the next major company files for an IPO. Daily alerts delivered to your inbox.
Get IPO Alerts